Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06571383 · ClinicalTrials.gov registry record · Phase 4
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
A Phase 4 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06571383 is a Phase 4 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 500 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06571383, a Phase 4 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Conditions Studied
Interventions
- DRUG Semaglutide
Study Locations (20)
Georgia
- Children's Healthcare Atlanta - Atlanta
- Columbus Research Foundation - Columbus
- Eastside Bariatric and Gen Surg - Snellville
Florida
- Clinical Neuroscience Solution - Orlando
- TMH Physician Partners Endo - Tallahassee
Ohio
- Centricity Research - Ohio - Columbus
- PriMed Clinical Research - Dayton
California
- Neighborhood Healthcare - Escondido
Idaho
- Solaris Clinical Research - Meridian
Illinois
- Synexus Clinical Research US Inc.-Chicago - Chicago
Indiana
- Indiana University Hospital - Indianapolis
Iowa
- University Of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2031-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06571383
The ClinicalTrials.gov registry entry for NCT06571383 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Semaglutide is the first listed.
NCT06571383 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Georgia, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT06571383 about?
NCT06571383 is a clinical study titled "STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss". The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All...
What is the current status of trial NCT06571383?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2024-09-17. Estimated completion is 2031-11-15.
What conditions does trial NCT06571383 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06571383?
The interventions under investigation include: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06571383?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06571383 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.